REGULATORY

MHLW Announces 1st Revision of Dyslipidemia Drug Development Guidelines in 30 Years

July 8, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) has revised guidelines for the clinical evaluation of dyslipidemia drugs for the first time in some 30 years in response to the accelerating global development of new modalities including small molecule compounds,…

To read the full story

MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
February 25, 2021
MHLW Study Group Drafting Guidelines for New Dyslipidemia Drug Development, First in 30 Years
June 11, 2019

REGULATORY

DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…